“Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s68. doi:10.25251/skin.4.supp.67.